Restructuring Activities

Due to economic conditions the Company has implemented a number of cost reduction or avoidance actions, including headcount reductions and facility closures and relocations relating to the consolidation of certain of our facilities in China, Buffalo BioMedical respiratory consolidation, and relocation of the corporate headquarters. The Buffalo Biomedical respiratory facility consolidation into Canton, Georgia, was completed during the first quarter of 2017. The E&C Wuxi, China facility consolidation was completed during the second quarter of 2017, and the D&S China facility consolidation is expected to be completed by the end of 2017. Our corporate headquarters move from Cleveland, Ohio to Canton, Georgia is substantially complete. The remainder of the corporate headquarters transition is expected to be finalized in the third quarter of 2017, and the Company’s Cleveland headquarters lease commitment ends December 2017.

The following table is a summary of the severance and other restructuring costs, which included employee-related costs, facility rent and exit costs, relocation, recruiting, travel and other, for the three months and six months ended June 30, 2017 and 2016:



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Severance:
Cost of sales	$	31	$	981	$	679	$	3,342
Selling, general, and administrative expenses	1,155		1,008		1,847		2,339
Total severance costs	$	1,186	$	1,989	$	2,526	$	5,681
Other restructuring:
Cost of sales	$	1,968	$	—	$	3,794	$	—
Selling, general, and administrative expenses	1,888		35		3,348		317
Total other restructuring costs	$	3,856	$	35	$	7,142	$	317

Total restructuring costs	$	5,042	$	2,024	$	9,668	$	5,998

The Company is closely monitoring its end markets and order rates and will continue to take appropriate and timely actions as necessary. The Company currently expects additional restructuring costs in the remaining six months of 2017 to be approximately $2,900 ($200 - E&C, $1,300 - D&S, $400 - BioMedical, and $1,000 - Corporate), but further actions may be required based on future business conditions.

The following tables summarize the Company’s restructuring activities for the three and six months ended June 30, 2017 and 2016:



	Three Months Ended June 30, 2017
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of March 31, 2017	$	—		$	2,265		$	1,439		$	2,931		$	6,635
Restructuring costs	1,657			300			1,407			1,678			5,042
Cash payments	(1,657		)	(700		)	(1,999		)	(3,116		)	(7,472		)
Balance as of June 30, 2017	$	—		$	1,865		$	847		$	1,493		$	4,205



	Three Months Ended June 30, 2016
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of March 31, 2016	$	544		$	5,254		$	474		$	1,075		$	7,347
Restructuring costs	369			1,618			37			—			2,024
Cash payments	(369		)	(2,076		)	(143		)	(799		)	(3,387		)
Balance as of June 30, 2016	$	544		$	4,796		$	368		$	276		$	5,984



	Six Months Ended June 30, 2017
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of December 31, 2016	$	127		$	2,864		$	1,308		$	3,025		$	7,324
Restructuring costs	2,083			437			4,011			3,137			9,668
Cash payments	(2,210		)	(1,436		)	(4,472		)	(4,669		)	(12,787		)
Balance as of June 30, 2017	$	—		$	1,865		$	847		$	1,493		$	4,205



	Six Months Ended June 30, 2016
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of December 31, 2015	$	1,106		$	3,446		$	430		$	850		$	5,832
Restructuring costs	662			3,811			521			1,004			5,998
Cash payments	(1,224		)	(2,461		)	(583		)	(1,578		)	(5,846		)
Balance as of June 30, 2016	$	544		$	4,796		$	368		$	276		$	5,984